Core Insights - Azenta, Inc. has been selected by the Crohn's & Colitis Foundation as the sample management services provider for two significant research cohorts, CAPTURE IBD and IBD SIRQC, focusing on pediatric and surgical care for inflammatory bowel disease [1][2] - The CAPTURE IBD study aims to enroll several thousand pediatric patients across 12 sites in the U.S., while the IBD SIRQC initiative plans to enroll 5,000 patients at 9 sites, tracking long-term surgical outcomes [2][3] - The partnership is expected to enhance the understanding of inflammatory bowel disease and support the development of precision medicine strategies [3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering a comprehensive suite of cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally [5] - The company is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia, and is known for its brands including GENEWIZ, FluidX, and others [5] Foundation Overview - The Crohn's & Colitis Foundation is a prominent nonprofit organization dedicated to research and patient support for inflammatory bowel disease, aiming to cure Crohn's disease and ulcerative colitis while improving the quality of life for affected individuals [4] - The Foundation's IBD Plexus® program provides a rich research ecosystem that links well-phenotyped data to biosamples, facilitating high-impact research [2][4]

BURLINGTON, Mass., May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (Nasdaq: AZT ...

Core Viewpoint - The article discusses the impact of inflation on consumers and businesses, leading to a rise in automation and robotics adoption, while highlighting specific robotics stocks that are recommended to sell due to declining performance and macroeconomic challenges [1]. Group 1: iRobot (IRBT) - iRobot has seen a significant contraction in sales growth, with revenue declining by more than 24% year-over-year for both fiscal years 2022 and 2023, marking the first time since 2017 that annual revenue fell below $1 billion [2][3]. - The decline in consumer confidence and high costs of new technologies have deterred purchases, prompting iRobot to announce a restructuring plan in January 2024, which includes operational cost cuts and leadership changes [3]. Group 2: Rockwell Automation (ROK) - Rockwell Automation operates in various industrial sectors but has faced sales declines, particularly in discrete and automotive sales, which fell in the "high single digits" due to challenges in the electric vehicle market [4][5]. - The company also reported declines in e-commerce and warehousing sales due to delayed modernization projects, with shares down 11.1% year-to-date as of the last trading session [5]. Group 3: Azenta (AZTA) - Azenta, a life sciences firm, has experienced a 13% year-over-year revenue decline in Q1 2024, with only a 7% increase in the second quarter, indicating weak sales growth for a largely loss-making company [6][7]. - Investors are concerned about Azenta's ability to reach breakeven, as the current revenue growth is insufficient to support its financial stability [7].

"We're thrilled to open our Oxford laboratory, which allows us to bring state-of-the-art NGS technology to UK researchers," said Dr Ginger Zhou, President of Azenta's Multiomics business unit.  "This new facility not only strengthens our global footprint but also offers researchers access to local experts and cutting-edge resources. The Oxford team comprises some of the best minds in the field, all with deep roots in the local scientific community." The opening event, held on April 25, 2024, featured a ribb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-30 ...

Azenta, Inc. (NASDAQ:AZTA) Q2 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Hannah Hefley - Stephens Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Matt Stanton - Jefferies Operator Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results. [Operator Instructions ...

Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024 BURLINGTON, Mass., May 8, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024. | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------|-------|----------------------|-------|-------------------------|---------|------------------------------|----------------------|-------------| | Dollars in ...

CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass., May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CEO until a successor is appointed to ensure a smooth transition. Dr. Schwartz's retirement follows a discussion with the Board as part of the company's active suc ...

BURLINGTON, Mass., April 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2023. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmenta ...

Financial Performance - Azenta's Q1 2024 revenue was $154 million, a 13% year-over-year decrease and a 15% decrease on an organic basis[7] - Non-GAAP EPS for Q1 2024 was $0.02, with an adjusted EBITDA of 30%[7] - The company's gross profit decreased from $81 million to $67 million, resulting in a gross profit margin decrease of 19 percentage points from 454% to 435%[9] - Azenta generated $15 million of free cash flow in Q1, marking the third consecutive quarter of positive free cash flow[7] Segment Performance - Sample Management Solutions (SMS) revenue reached $79 million, showing a 5% year-over-year increase, but only a 1% organic growth[12] - Excluding Consumables & Instruments (C&I), SMS organic growth was 9% year-over-year[8] - Multiomics revenue was $63 million, a 3% year-over-year increase, with 2% organic growth[15] - B Medical Systems experienced a 70% year-over-year revenue decline, primarily due to order timing in the vaccine cold chain[8] Balance Sheet and Capital Allocation - Azenta maintains a strong balance sheet with a cash balance of $11 billion as of December 31, 2023[7] - The company returned $113 million of capital through the repurchase of 23 million shares in Q1[7] - Approximately $500 million in cash remains available for disciplined and long-term value-creating initiatives after committed repurchases[7] Fiscal Year 2024 Guidance - Azenta anticipates organic revenue growth of 5% to 8%, with revenue projected between $696 million and $718 million[19] - The company expects an approximate 300 basis point margin improvement in adjusted EBITDA[19]